Rasburicase has 34 known drug interactions based on U.S. FDA drug labeling data. 26 are classified as major interactions requiring close medical supervision. Notable interactions include combinations with Articaine Hydrochloride And Epinephrine, Articaine Hydrochloride And Epinephrine Bitartrate, Benzocaine, Butamben, And Tetracaine Hydrochloride. Patients taking Rasburicase should inform their healthcare provider of all current medications — including over-the-counter drugs and supplements — to avoid potentially harmful combinations. Data sourced from OpenFDA and the NIH National Library of Medicine.
- Total
- 34
- Major
- 26
- Moderate
- 6
Major (26)
- Rasburicase + Articaine Hydrochloride And Epinephrine— Increased risk of methemoglobinemia when concurrently exposed to articaine.
- Rasburicase + Articaine Hydrochloride And Epinephrine Bitartrate— Increased risk of developing methemoglobinemia when concurrently exposed to this antineoplastic agent.
- Rasburicase + Benzocaine, Butamben, And Tetracaine Hydrochloride— Increased risk of methemoglobinemia when concurrently exposed to this antineoplastic oxidizing agent with local anesthet…
- Rasburicase + Bupivacaine And Meloxicam— Increased risk of methemoglobinemia when local anesthetics are used concomitantly with antineoplastic agents.
- Rasburicase + Bupivacaine Hydrochloride— Increased risk of methemoglobinemia when concurrently exposed with bupivacaine.
- Rasburicase + Dexamethasone Sodium Phosphate, Lidocaine Hydrochloride, Povidine Iodine— Antineoplastic agent associated with increased methemoglobinemia risk when used with ropivacaine.
- Rasburicase + Lidocaine— Increased risk of methemoglobinemia when used concurrently with lidocaine.
- Rasburicase + Lidocaine 5%— Antineoplastic agent that may cause methemoglobinemia when used concomitantly with lidocaine patch 5%.
- Rasburicase + Lidocaine And Capsaicin— Antineoplastic agent that increases risk of methemoglobinemia when used concurrently with lidocaine and capsaicin patch.
- Rasburicase + Lidocaine And Prilocaine— Antineoplastic agent; increased risk of methemoglobinemia when concurrently exposed.
- Rasburicase + Lidocaine Hydrochloride— Increased risk of methemoglobinemia when used concurrently with lidocaine hydrochloride.
- Rasburicase + Lidocaine Hydrochloride And Epinephrine Bitartrate— Antineoplastic agent associated with increased methemoglobinemia risk when used concurrently.
- Rasburicase + Lidocaine Hydrochloride And Hydrocortisone Acetate— Increased risk of methemoglobinemia when local anesthetic is concurrently exposed to antineoplastic agents.
- Rasburicase + Lidocaine Hydrochloride Monohydrate— Concurrent exposure increases risk of methemoglobinemia in patients administered local anesthetics.
- Rasburicase + Lidocaine Patch 5%— Increased risk of methemoglobinemia; antineoplastic agents associated with methemoglobinemia when used with local anesth…
- Rasburicase + Lidocaine, Isopropyl Alcohol— Increased risk of methemoglobinemia when used with lidocaine.
- Rasburicase + Lidocaine, Menthol— Increased risk of methemoglobinemia when lidocaine is concurrently exposed to antineoplastic agents.
- Rasburicase + Lidothol Patch— Increased risk of methemoglobinemia when local anesthetics are concurrently exposed to antineoplastic agents.
- Rasburicase + Marcaine, Lidocaine, Kenalog, Povidone Iodine— Increased risk of methemoglobinemia when concurrently exposed to antineoplastic agents.
- Rasburicase + Mepivacaine Hydrochloride— Concurrent exposure increases risk of methemoglobinemia in patients administered mepivacaine.
- Rasburicase + Prilocaine Hcl And Epinephrine— Increased risk of methemoglobinemia when prilocaine is concurrently exposed to rasburicase.
- Rasburicase + Prilocaine Hydrochloride— Increased risk of methemoglobinemia when used concurrently with prilocaine.
- Rasburicase + Ropivacaine Hydrochloride— Increased risk of developing methemoglobinemia when concurrently exposed to rasburicase.
- Rasburicase + Triamcinolone Acetonide— Increased risk of methemoglobinemia when concurrently exposed.
- Rasburicase + Triethanolamine Salicylate— Increased risk of methemoglobinemia when used concurrently with triethanolamine salicylate.
- Rasburicase + Trubrexa Patch Er— Increased risk of methemoglobinemia when used with Trubrexa Transdermal Patch.
Moderate (6)
- Rasburicase + Bupivacaine— May increase risk of methemoglobinemia when concurrently exposed with bupivacaine.
- Rasburicase + Bupivacaine Hydrochloride And Epinephrine Bitartrate— Increased risk of methemoglobinemia when concurrently exposed.
- Rasburicase + Bupivacaine Hydrochloride With Dextrose— Increased risk of developing methemoglobinemia when concurrently exposed.
- Rasburicase + Lidocaine And Tetracaine— Antineoplastic agent that increases risk of methemoglobinemia when used concomitantly with lidocaine and tetracaine.
- Rasburicase + Marcaine, Kenalog, Povidone Iodine— Increased risk of methemoglobinemia when concurrently exposed to antineoplastic agents with bupivacaine.
- Rasburicase + Penicillin G Benzathine And Penicillin G Procaine— Increased risk of methemoglobinemia when concurrently exposed with local anesthetics (procaine is a component of this dr…